Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Mitochondrial Pyruvate Carrier (MPC) complex is a hetero-oligomeric transporter located in the inner mitochondrial membrane, primarily composed of the subunits MPC1 and MPC2 (Bricker et al., 2012; Herzig et al., 2012). Its primary biological function is to facilitate the transport of pyruvate from the cytosol into the mitochondrial matrix, a critical step that links glycolysis to the tricarboxylic acid (TCA) cycle and gluconeogenesis (McCommis & Finck, 2015; Gray et al., 2014). By controlling the entry of pyruvate into the mitochondria, the MPC serves as a key metabolic gatekeeper, influencing energy production and biosynthetic pathways (Taylor et al., 2012). MPC2 is recognized as the primary binding subunit for several classes of inhibitors, including thiazolidinedione-like insulin sensitizers (Colca et al., 2014; Divakaruni et al., 2013). In diseases such as type 2 diabetes and non-alcoholic steatohepatitis (NASH), the MPC is a strategic therapeutic target (McCommis et al., 2017; Harrison et al., 2020). Inhibition of the MPC can reduce hepatic glucose production and improve insulin sensitivity by altering mitochondrial fuel utilization (Vigueira et al., 2014; McCommis et al., 2015). In oncology, the MPC's role is context-dependent; it is often downregulated in tumors to promote the Warburg effect, but its inhibition can also be used to starve certain cancers of mitochondrial metabolites (Schell et al., 2014; Bensard et al., 2020). Clinical candidates like MSDC-0602K and MSDC-0160 target the MPC to treat metabolic and neurodegenerative conditions, respectively, by modulating systemic energy homeostasis (Shah et al., 2014; ClinicalTrials.gov NCT02784444). Recent structural studies have elucidated the rocker-switch mechanism of the MPC, providing a blueprint for the design of more selective inhibitors (Sichrovsky et al., 2024).
Inhibition of mitochondrial pyruvate transport
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial pyruvate carrier complex (MPC).